Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

Also called NCT03210532

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 129 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03210532
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03210532. Randomized; double masking; primary purpose treatment. Start 2016-10-07 (actual); primary completion 2017-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia
Condition
Hypertension
Condition
Dyslipidemia
Intervention (Drug)
Telmisartan + Amlodipine + Rosuvastatin
Intervention (Drug)
Telmisartan + Amlodipine
Intervention (Drug)
Telmisartan + Rosuvastatin
Lead sponsor
Daewon Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03210532
Content hash
5c726594682159f65ba533ecd68f415c3416c6ce695bbc50f9dc7c73b3937737